Jinwon Life Sciences Subsidiary VGXI Forms Strategic Partnership with Sutro Biopharma
Jinwon Life Sciences announced on the 4th that its subsidiary VGXI, a leading contract development and manufacturing organization (CDMO) in the field of nucleic acid biopharmaceuticals such as gene therapy, DNA vaccines, and RNA drugs, has formed a strategic partnership with Nasdaq-listed Sutro Biopharma, Inc. VGXI will be responsible for producing plasmid DNA used in clinical trials of luveltamab tazevibulin (luvelta), an antibody-drug conjugate (ADC) anticancer agent developed by Sutro Biopharma.
Sutro Biopharma, a clinical-stage ADC anticancer drug developer targeting ovarian cancer, recently initiated Part 2 studies for the global Phase 2/3 clinical trial of luvelta. VGXI will produce and supply the plasmid DNA required for Sutro Biopharma’s XpressCF cell-free expression system for luvelta manufacturing using a 1500L fermenter.
Youngkeun Park, CEO of Jinwon Life Sciences, said, “We are pleased to establish a strategic partnership to support not only the clinical production of luvelta but also all ongoing projects of Sutro Biopharma. Our company’s expertise and technology in large-scale plasmid DNA production will play a crucial role in advancing and commercializing Sutro Biopharma’s promising therapeutics in late-stage clinical development.”
Hot Picks Today
Boyfriend Used It for Free, I Had to Pay... Woman in Her 20s Sues Over 'Gender Discrimination' Restroom Fees
- "Was This Delicious Gimbap Only for Koreans?" Sold Out at $28 a Roll... Gimbap Debuts at US Tennis Mecca
- "With Foreign Tourists Flocking to Korea, Calls Grow to Raise Departure Tax Like Hong Kong and Japan... Legislation Gains Speed"
- "We'll Get at Least 30 Million Won a Month"... Cheongdam-dong Landlords Won't Lower Rent Despite Year-Long Vacancies
- "Jeju Should Not Be Taken Lightly... Do Not Walk Alone Even in Broad Daylight," Warns Jeju Resident of 7 Years, Hyegul Hong
Dr. Venkatesh Srinivasan, Chief Technology and Operations Officer of Sutro Biopharma, stated, “The partnership with VGXI has laid the foundation for further activating the cell-free manufacturing platform at a commercial scale as leading drug candidates progress into clinical development.”
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.
